[go: up one dir, main page]

WO1999031262A3 - Needle-free injection of formulated nucleic acid molecules - Google Patents

Needle-free injection of formulated nucleic acid molecules Download PDF

Info

Publication number
WO1999031262A3
WO1999031262A3 PCT/US1998/026823 US9826823W WO9931262A3 WO 1999031262 A3 WO1999031262 A3 WO 1999031262A3 US 9826823 W US9826823 W US 9826823W WO 9931262 A3 WO9931262 A3 WO 9931262A3
Authority
WO
WIPO (PCT)
Prior art keywords
nucleic acid
acid molecules
methods
needle
disclosed
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US1998/026823
Other languages
French (fr)
Other versions
WO1999031262A2 (en
Inventor
Michael Barry
Russ Mumper
Lou Smith
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Baylor College of Medicine
Urigen Pharmaceuticals Inc
Original Assignee
Baylor College of Medicine
Urigen Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Baylor College of Medicine, Urigen Pharmaceuticals Inc filed Critical Baylor College of Medicine
Priority to AU19229/99A priority Critical patent/AU1922999A/en
Priority to EP98964020A priority patent/EP1038016A2/en
Priority to JP2000539160A priority patent/JP2003528024A/en
Priority to CA002315256A priority patent/CA2315256A1/en
Publication of WO1999031262A2 publication Critical patent/WO1999031262A2/en
Publication of WO1999031262A3 publication Critical patent/WO1999031262A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/10—Drugs for disorders of the endocrine system of the posterior pituitary hormones, e.g. oxytocin, ADH

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Genetics & Genomics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Virology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Endocrinology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Oncology (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Diabetes (AREA)
  • Communicable Diseases (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Infusion, Injection, And Reservoir Apparatuses (AREA)
  • Apparatus Associated With Microorganisms And Enzymes (AREA)

Abstract

A novel method is provided for delivering nucleic acid molecules through and/or to the skin of mammals by needle-free injection. The method involves the incorporation of formulated nucleic acid molecules with devices for injecting the molecules by air, fluid and/or mechanical pressure. Disclosed are compositions and methods for enhancing the administration to and uptake of nucleic acids in a mammal. The methods disclosed provide an increased immune response by allowing the uptake of formulated nucleic acid molecules by a wide variety of cell types simultaneously. Also disclosed are examples which demonstrate that the combination of formulated nucleic acid molecules and needle-free injection methods results in immune responses which are superior to those obtained by conventional means of delivery. Methods for delivery, as well as methods for formulating nucleic acid molecules with various compounds, such as cationic complexing agents, polymeric and non-polymeric formulations, protective, interactive, non-condensing systems are also disclosed.
PCT/US1998/026823 1997-12-16 1998-12-16 Needle-free injection of formulated nucleic acid molecules Ceased WO1999031262A2 (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
AU19229/99A AU1922999A (en) 1997-12-16 1998-12-16 Needle-free injection of formulated nucleic acid molecules
EP98964020A EP1038016A2 (en) 1997-12-16 1998-12-16 Needle-free injection of formulated nucleic acid molecules
JP2000539160A JP2003528024A (en) 1997-12-16 1998-12-16 Needle-free injection of formulated nucleic acid molecules
CA002315256A CA2315256A1 (en) 1997-12-16 1998-12-16 Needle-free injection of formulated nucleic acid molecules

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US6975497P 1997-12-16 1997-12-16
US60/069,754 1997-12-16

Publications (2)

Publication Number Publication Date
WO1999031262A2 WO1999031262A2 (en) 1999-06-24
WO1999031262A3 true WO1999031262A3 (en) 1999-09-10

Family

ID=22091009

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1998/026823 Ceased WO1999031262A2 (en) 1997-12-16 1998-12-16 Needle-free injection of formulated nucleic acid molecules

Country Status (5)

Country Link
EP (1) EP1038016A2 (en)
JP (1) JP2003528024A (en)
AU (1) AU1922999A (en)
CA (1) CA2315256A1 (en)
WO (1) WO1999031262A2 (en)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7517864B2 (en) 2001-05-18 2009-04-14 Sirna Therapeutics, Inc. RNA interference mediated inhibition of vascular endothelial growth factor and vascular endothelial growth factor receptor gene expression using short interfering nucleic acid (siNA)
US11932854B2 (en) 2010-10-29 2024-03-19 Sirna Therapeutics, Inc. RNA interference mediated inhibition of gene expression using short interfering nucleic acids (siNA)

Families Citing this family (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7393529B2 (en) 1998-04-09 2008-07-01 Idexx Laboratories, Inc. Methods and compositions for inhibiting binding of IgE to a high affinity receptor
EP1200119A2 (en) * 1999-07-20 2002-05-02 Pharmexa A/S Method for down-regulating gdf-8 activity
US6562623B1 (en) 1999-07-21 2003-05-13 Immunoporation Ltd Method for introducing a substance into a cell
US7196066B1 (en) * 1999-11-03 2007-03-27 Powderject Vaccines, Inc. DNA-vaccines based on constructs derived from the genomes of human and animal pathogens
US8273866B2 (en) 2002-02-20 2012-09-25 Merck Sharp & Dohme Corp. RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (SINA)
US8202979B2 (en) 2002-02-20 2012-06-19 Sirna Therapeutics, Inc. RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid
US6875748B2 (en) 2000-04-21 2005-04-05 Vical Incorporated Compositions and methods for in vivo delivery of polynucleotide-based therapeutics
US9994853B2 (en) 2001-05-18 2018-06-12 Sirna Therapeutics, Inc. Chemically modified multifunctional short interfering nucleic acid molecules that mediate RNA interference
US20050148530A1 (en) 2002-02-20 2005-07-07 Sirna Therapeutics, Inc. RNA interference mediated inhibition of vascular endothelial growth factor and vascular endothelial growth factor receptor gene expression using short interfering nucleic acid (siNA)
FR2835749B1 (en) * 2002-02-08 2006-04-14 Inst Nat Sante Rech Med PHARMACEUTICAL COMPOSITION IMPROVING IN VIVO GENE TRANSFER
AU2003207708A1 (en) 2002-02-20 2003-09-09 Sirna Therapeutics, Inc. Rna interference mediated inhibition of map kinase genes
US9181551B2 (en) 2002-02-20 2015-11-10 Sirna Therapeutics, Inc. RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA)
US9657294B2 (en) 2002-02-20 2017-05-23 Sirna Therapeutics, Inc. RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA)
US7956176B2 (en) 2002-09-05 2011-06-07 Sirna Therapeutics, Inc. RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA)
ATE495189T1 (en) 2003-08-15 2011-01-15 Univ Florida THE IDENTIFICATION OF POLYNUCLEOTIDES OF PORPHYROMONAS GINGIVALIS VIRULENCE FOR THE DIAGNOSIS, TREATMENT AND MONITORING OF PERIODONTAL DISEASES
US20070293447A1 (en) * 2003-08-29 2007-12-20 Yasuo Kunugiza Gene Therapy for Skin Disorders Using Needleless Syringes
ES2394799T3 (en) 2003-12-31 2013-02-05 The Penn State Research Foundation Methods to predict and overcome chemotherapy resistance in ovarian cancer
JP2005335054A (en) * 2004-04-27 2005-12-08 Japan Science & Technology Agency Metal nanowire and manufacturing method thereof
US20060040882A1 (en) 2004-05-04 2006-02-23 Lishan Chen Compostions and methods for enhancing delivery of nucleic acids into cells and for modifying expression of target genes in cells
US10508277B2 (en) 2004-05-24 2019-12-17 Sirna Therapeutics, Inc. Chemically modified multifunctional short interfering nucleic acid molecules that mediate RNA interference
EP2298896A1 (en) 2004-06-22 2011-03-23 The Board of Trustees of the University of Illinois Methods of inhibiting tumor cell proliferation with FOXM1 siRNA
WO2006058426A1 (en) * 2004-12-01 2006-06-08 Wlt Distributors Inc. Needle-free injector
US20120208824A1 (en) 2006-01-20 2012-08-16 Cell Signaling Technology, Inc. ROS Kinase in Lung Cancer
ES2683846T3 (en) 2006-01-20 2018-09-28 Cell Signaling Technology, Inc. ROS mutant and translocation kinase in human non-small cell lung carcinoma
DK2450437T3 (en) 2006-04-14 2017-09-11 Cell Signaling Technology Inc Gene defects and mutant ALK kinase in human solid tumors
CN104531701A (en) 2006-07-21 2015-04-22 赛伦斯治疗有限公司 Means for inhibiting the expression of protein kinase 3
US8188214B2 (en) 2007-02-28 2012-05-29 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Brachyury polypeptides and methods for use
CN101674853B (en) 2007-05-04 2013-03-27 玛瑞纳生物技术有限公司 Amino acid lipids and uses thereof
US9096855B2 (en) 2007-10-18 2015-08-04 Cell Signaling Technology, Inc. Translocation and mutant ROS kinase in human non-small cell lung carcinoma
JP5667043B2 (en) 2008-04-15 2015-02-12 アメリカ合衆国ＧＯＶＥＲＮＭＥＮＴ ＯＦ ＴＨＥ ＵＮＩＴＥＤ ＳＴＡＴＥＳ ＯＦ ＡＭＥＲＩＣＡ， ａｓ ｒｅｐｒｅｓｅｎｔｅｄ ｂｙ ＴＨＥ ＳＥＣＲＥＴＡＲＹ， ＤＥＰＡＲＴＭＥＮＴ ＯＦ ＨＥＡＬＴＨＡＮＤ ＨＵＭＡＮ ＳＥＲＶＩＣＥＳ Compositions and methods for delivering inhibitory oligonucleotides
CA2726187A1 (en) 2008-05-30 2009-12-23 Yale University Targeted oligonucleotide compositions for modifying gene expression
BRPI0920171A2 (en) 2008-10-16 2016-07-12 Marina Biotech Inc processes and compositions for liposomal and efficient release of gene silencing therapies.
HUE035769T2 (en) 2009-02-12 2018-05-28 Cell Signaling Technology Inc Mutant ROS expression in human liver cancer
HUE028036T2 (en) 2009-04-10 2016-11-28 Ass Inst De Myologie Tricyclo-dna antisense oligonucleotides, compositions, and methods for the treatment of disease
KR101692063B1 (en) 2009-12-09 2017-01-03 닛토덴코 가부시키가이샤 MODULATION OF hsp47 EXPRESSION
WO2011120023A1 (en) 2010-03-26 2011-09-29 Marina Biotech, Inc. Nucleic acid compounds for inhibiting survivin gene expression uses thereof
WO2011133584A2 (en) 2010-04-19 2011-10-27 Marina Biotech, Inc. Nucleic acid compounds for inhibiting hras gene expression and uses thereof
WO2011139843A2 (en) 2010-04-28 2011-11-10 Marina Biotech, Inc. Multi-sirna compositions for reducing gene expression
WO2011146938A1 (en) 2010-05-21 2011-11-24 NanoOncology, Inc. Reagents and methods for treating cancer
SG186438A1 (en) 2010-06-24 2013-01-30 Quark Pharmaceuticals Inc Double stranded rna compounds to rhoa and use thereof
US20120101108A1 (en) 2010-08-06 2012-04-26 Cell Signaling Technology, Inc. Anaplastic Lymphoma Kinase In Kidney Cancer
KR20130137160A (en) 2010-08-24 2013-12-16 머크 샤프 앤드 돔 코포레이션 Single-stranded rnai agents containing an internal, non-nucleic acid spacer
US20140134231A1 (en) 2010-10-11 2014-05-15 Sanford-Burnham Medical Research Institute Mir-211 expression and related pathways in human melanoma
US8680045B2 (en) 2010-11-01 2014-03-25 Peptimed, Inc. Compositions of a peptide targeting system for treating cancer
KR101937498B1 (en) 2011-03-03 2019-04-10 쿠아크 파마수티칼스 인코퍼레이티드 Compositions and methods for treating lung disease and injury
DE102011018499A1 (en) 2011-04-23 2012-10-25 Emc Microcollections Gmbh Topical nanoparticle vaccine for the immune stimulation of dendritic cells in the skin
EP2581448B1 (en) 2011-10-13 2015-01-28 Association Institut de Myologie Tricyclo-phosphorothioate DNA
WO2013106494A1 (en) 2012-01-12 2013-07-18 Quark Pharmaceuticals, Inc. Combination therapy for treating hearing and balance disorders
US20150056193A1 (en) 2012-04-18 2015-02-26 Cell Signaling Technology, Inc. Egfr and ros1 kinase in cancer
EP3919620A1 (en) 2012-05-02 2021-12-08 Sirna Therapeutics, Inc. Short interfering nucleic acid (sina) compositions
AU2013315524B2 (en) 2012-09-12 2019-01-31 Quark Pharmaceuticals, Inc. Double-stranded oligonucleotide molecules to p53 and methods of use thereof
CN104619844A (en) 2012-09-12 2015-05-13 夸克制药公司 Double-stranded oligonucleotide molecules to p53 and methods of use thereof
US9884886B2 (en) 2012-12-06 2018-02-06 Merck Sharp & Dohme Disulfide masked prodrug compositions and methods
WO2015020960A1 (en) 2013-08-09 2015-02-12 Novartis Ag Novel lncrna polynucleotides
US10111898B2 (en) 2014-08-27 2018-10-30 Peptimed, Inc. Anti-tumor compositions and methods
WO2017184586A1 (en) 2016-04-18 2017-10-26 The Trustees Of Columbia University In The City Of New York Therapeutic targets involved in the progression of nonalcoholic steatohepatitis (nash)
EP4275717A4 (en) * 2021-01-05 2024-06-26 Daicel Corporation Injector

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1990011092A1 (en) * 1989-03-21 1990-10-04 Vical, Inc. Expression of exogenous polynucleotide sequences in a vertebrate
WO1994024263A1 (en) * 1993-04-08 1994-10-27 Oxford Biosciences Limited Needleless syringe using supersonic gas flow for particle delivery
WO1994024983A2 (en) * 1993-04-28 1994-11-10 Ribozyme Pharmaceuticals, Inc. Ocular delivery of nucleic acid
WO1996020732A2 (en) * 1994-12-30 1996-07-11 Chiron Corporation Non-traumatic administration of gene delivery vehicles
WO1996034967A1 (en) * 1995-05-04 1996-11-07 Board Of Trustees Of The Leland Stanford Junior University, The Office Of Technology Licensing Apparatus and method for delivering a nucleotide into cell nuclei
WO1996040958A1 (en) * 1995-06-07 1996-12-19 Baylor College Of Medicine Nucleic acid transporters for delivery of nucleic acids into a cell

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1990011092A1 (en) * 1989-03-21 1990-10-04 Vical, Inc. Expression of exogenous polynucleotide sequences in a vertebrate
WO1994024263A1 (en) * 1993-04-08 1994-10-27 Oxford Biosciences Limited Needleless syringe using supersonic gas flow for particle delivery
WO1994024983A2 (en) * 1993-04-28 1994-11-10 Ribozyme Pharmaceuticals, Inc. Ocular delivery of nucleic acid
WO1996020732A2 (en) * 1994-12-30 1996-07-11 Chiron Corporation Non-traumatic administration of gene delivery vehicles
WO1996034967A1 (en) * 1995-05-04 1996-11-07 Board Of Trustees Of The Leland Stanford Junior University, The Office Of Technology Licensing Apparatus and method for delivering a nucleotide into cell nuclei
WO1996040958A1 (en) * 1995-06-07 1996-12-19 Baylor College Of Medicine Nucleic acid transporters for delivery of nucleic acids into a cell

Non-Patent Citations (14)

* Cited by examiner, † Cited by third party
Title
BARRY, MICHAEL A. ET AL: "Biological features of genetic immunization.", VACCINE, (1997) VOL. 15, NO. 8, PP. 788-791. ISSN: 0264-410X., XP002099107 *
BRANDSMA J L ET AL: "USE OF A RAPID, EFFICIENT INOCULATION METHOD TO INDUCE PAPILLOMAS BY COTTONTAIL RABBIT PAPILLOMAVIRUS DNA SHOWS THAT THE E7 GENE IS REQUIRED", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF USA, vol. 88, June 1991 (1991-06-01), pages 4816 - 4820, XP002064169 *
CURIEL D T ET AL: "HIGH-EFFICIENCY GENE TRANSFER MEDIATED BY ADENOVIRUS COUPLED TO DNA-POLYLYSINE COMPLEXES", HUMAN GENE THERAPY, vol. 3, no. 2, 1 April 1992 (1992-04-01), pages 147 - 154, XP000579759 *
D.E.KERR ET AL.: "Ovine mammary gland expression of jet-injected plasmid DNA: Northern blot and antibody analysis.", JOURNAL OF CELLULAR BIOCHEMISTRY SUPPLEMENT, vol. 0, no. 21a, 1995, pages 395, XP002099108 *
FELGNER P L ET AL: "LIPOFECTION: A HIGHLY EFFICIENT, LIPID-MEDIATED DNA-TRANSFECTION PROCEDURE", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF USA, vol. 84, November 1987 (1987-11-01), pages 7413 - 7417, XP002015347 *
FURTH P A ET AL: "GENE TRANSFER INTO SOMATIC TISSUES BY JET INJECTION", ANALYTICAL BIOCHEMISTRY, vol. 205, September 1992 (1992-09-01), pages 365 - 368, XP000647725 *
FURTH, PRISCILLA A. (1) ET AL: "Gene Transfer into Mammalian Cells by Jet Injection.", HYBRIDOMA, (1995) VOL. 14, NO. 2, PP. 149-152. ISSN: 0272-457X., XP002064168 *
GONZALEZ J.L. ET AL: "Psychological responses to the needle - free injection of insulin with the disposable front-end Medi-Jector.RTM. (MJ-6).", TODAY'S THERAPEUTIC TRENDS, (1998) 16/1 (53-71). REFS: 21 ISSN: 0741-2320 CODEN: TTTRDH, UNITED STATES, XP002099112 *
H.L. DAVIES ET AL.: "Direct gene transfer in skeletal muscle: plasmid DNA-based immunization against the hepatitis B virus surface antigen.", VACCINE, vol. 12, no. 16, 1994, pages 1503 - 1509, XP002099109 *
HAYNES, JOEL R. (1) ET AL: "Induction and characterization of humoral and cellular immune responses elicited via gene gun -mediated nucleic acid immunization.", ADVANCED DRUG DELIVERY REVIEWS, (1996) VOL. 21, NO. 1, PP. 3-18. ISSN: 0169-409X., XP002099106 *
JOHNSTON S A ET AL: "GENE GUN TRANSFECTION OF ANIMAL CELLS AND GENETIC IMMUNIZATION", METHODS IN CELL BIOLOGY, vol. 43, 1 January 1994 (1994-01-01), pages 353 - 365, XP000575592 *
LONGRIDGE, D. J. ET AL: "Effects of payload per unit area on dermal Powderject delivery of testosterone to conscious rabbits", PROC. INT. SYMP. CONTROLLED RELEASE BIOACT. MATER. (1998), 25TH, 595-596 CODEN: PCRMEY;ISSN: 1022-0178, 1998, XP002099110 *
ROGGE M.C. ET AL: "Impaired bioavailability of interferon beta-1a when administered intramuscularly by needle - free injection.", DRUG DELIVERY: JOURNAL OF DELIVERY AND TARGETING OF THERAPEUTIC AGENTS, (1998) 5/4 (275-280). REFS: 12 ISSN: 1071-7544 CODEN: DDELEB, UNITED STATES, XP002099111 *
WAGNER E ET AL: "TRANSFERRIN-POLYCATION CONJUGATED AS CARRIERS FOR DNA UPTAKE INTO CELLS", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF USA, vol. 87, 1 May 1990 (1990-05-01), pages 3410 - 3414, XP002002759 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7517864B2 (en) 2001-05-18 2009-04-14 Sirna Therapeutics, Inc. RNA interference mediated inhibition of vascular endothelial growth factor and vascular endothelial growth factor receptor gene expression using short interfering nucleic acid (siNA)
US11932854B2 (en) 2010-10-29 2024-03-19 Sirna Therapeutics, Inc. RNA interference mediated inhibition of gene expression using short interfering nucleic acids (siNA)

Also Published As

Publication number Publication date
EP1038016A2 (en) 2000-09-27
WO1999031262A2 (en) 1999-06-24
CA2315256A1 (en) 1999-06-24
JP2003528024A (en) 2003-09-24
AU1922999A (en) 1999-07-05

Similar Documents

Publication Publication Date Title
WO1999031262A3 (en) Needle-free injection of formulated nucleic acid molecules
WO1997000965A3 (en) A lipidic vector for nucleic acid delivery
BR9913712A (en) Pharmaceutical or veterinary process and composition for prophylactic or therapeutic inhibition of a microbial or parasitic agent in a human or non-human animal patient, and use of an anionic or cationic dendrimer
WO1999002186A3 (en) Antigen delivery system comprising monoglyceride or diglyceride derivatives as adjuvant
BR0011347A (en) Preparations and forms of administration comprising an active unstable acid compound
EP0293852A3 (en) Alpha, beta-unsaturated carbonyl-functional silicone compositions
WO2001081609A3 (en) Compositions and methods for generating an immune response utilizing alphavirus-based vector systems
ES2102919T3 (en) ACID COMPOSITION BASED ON LIPID VESICLES AND ITS USE IN TOPICAL APPLICATION
WO1999004820A3 (en) Cytolysis of target cells by superantigen conjugates inducing t-cell activation
WO2005016239A3 (en) Molecules enhancing dermal delivery of influenza vaccines
WO2000009086A3 (en) Protected one-vial formulation for nucleic acid molecules, methods of making the same by in-line mixing, and related products and methods
WO1998046270A3 (en) Polymeric conjugates polyvalently presenting an agent for therapy
EP0431173A4 (en) Curing agent, method of preparation thereof, and curable composition prepared therefrom
DK0666762T3 (en) Process for the preparation of lipid conjugates
SG54968A1 (en) Fuel additive
PT692974E (en) CLOSTRIDAL VACCINES WITH MULTIPLE COMPONENTS USING SAPONIN ADJUVANTS
Fleck et al. Adjuvant activity in delayed hypersensitivity of the peptidic part of bacterial peptidoglycans
DE60228615D1 (en) MEDICAL AEROSOL COMPOSITIONS WITH AN EXCIPIENT COMPOUND CONTAINING AN AMID AND / OR ESTER GROUP
IL98273A (en) Dna sequences, proteins having esterase activity coded by them and use of such proteins, pharmaceutical compositions and infant food formulations containing the proteins and processes for preparing them
WO2000057908A3 (en) Attenuated dengue-1 virus vaccine
WO1993013797A3 (en) Detoxified lps-cholera toxin conjugate vaccine for prevention of cholera
WO2000057904A3 (en) Attenuated dengue-3 virus vaccine
DE69624563D1 (en) PHARMACEUTICAL COMPOSITION PRODUCED BY ADDING A TASTE TO AN ACTIVE SUBSTANCE
JPS56157425A (en) Curable resin composition
BR0111701A (en) Method for reducing or eliminating effervescence and / or syneresis in a gel formulation

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
AK Designated states

Kind code of ref document: A3

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
ENP Entry into the national phase

Ref document number: 2315256

Country of ref document: CA

Ref country code: CA

Ref document number: 2315256

Kind code of ref document: A

Format of ref document f/p: F

ENP Entry into the national phase

Ref country code: JP

Ref document number: 2000 539160

Kind code of ref document: A

Format of ref document f/p: F

NENP Non-entry into the national phase

Ref country code: KR

WWE Wipo information: entry into national phase

Ref document number: 19229/99

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 1998964020

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1998964020

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWW Wipo information: withdrawn in national office

Ref document number: 1998964020

Country of ref document: EP